Ref ID: 12753
Author:
Cassone, A.
Author address:
Department of Infectious Diseases, Istituto Superiore di Sanití , Rome, Italy
Full conference title:
3rd Trends in Medical Mycology
Date: 28 October 2014
Abstract:
Vaccines against human pathogenic fungi , a rather neglected medical need until
few years ago, are now gaining steps in the public health priority scale. At variance with almost all other vaccines which are designed to immunize healthy,
immunocompetent subjects, fungal vaccines must be designed to provide protection in immunocompromized subjects who are the common targets of fungal infections, and this represents a novel, quite formidable challenge for vaccinologists. Nevertheless, with rising knowledge of the multiple determinants of host-fungus relationship, and the spectacular advances in genome sequencing, genetic engineering and proteomics, a remarkable progress strong progress is being made in
this area. Realistic targets for fungal vaccines have been identified even in
profoundly immunodepressed hemopathic, stem-cell transplanted patients and those affected by solid tumors and receiving aggressive chemotherapy. In experimental
models, some vaccines induce the generation of directly fungicidal antibodies and others are protective in animals carrying major risk factors for fungal infections such as CD4+ T cell deficiency or neutropenia. Moreover, antibodies have been discovered that may have a strong impact in the protection against fungal infection as
passive vaccination or immunotherapy, even beyond the role of antibodies in the natural history of infection. This discovery has greatly contributed to the
advancements in the field of fungal vaccines, in recognition that almost all useful vaccines against viral and bacterial pathogens owe their protective efficacy to neutralizing, opsonizing or otherwise effective antibodies. Overall, there is more hope now than few years ago about the chances of generating and having approved by the regulatory authorities one or more antifungal vaccines , be active or passive, for use in humans in the next few years. In particular, the possibility of protecting against
multiple opportunistic mycoses in immuno-depressed subjects with a single, well-defined glucan-conjugate vaccine, eliciting growth-inhibitory anti-fungal antibodies may be an important step to achieve this critical public health goal. (Supported by ISS/EC grants)
Abstract Number: PS1.1
Slides: y
Conference Year: 2007
Link to conference website: NULL
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Teclegiorgis Gebremariam [MS]1, Yiyou Gu [PhD]1, Sondus Alkhazraji [PhD]1, Jousha Quran1, Laura K. Najvar [BS]2, Nathan P. Wiederhold [PharmD]2, Thomas F. Patterson [MD]2, Scott G. Filler [MD]1,3, David A. Angulo (MD)4, Ashraf S. Ibrahim [PhD]1,3*,
2024
91
n/a
-
v
Ruta Petraitiene (US)
2024
90
n/a
-
v
Fabio Palmieri (CH), Junier Pilar
2024
89
n/a
-
v
Evelyne Côté (CA)
2024
88
n/a
-
v
Eliane Vanhoffelen (BE)
2024
87
n/a
-
v
Teclegiorgis Gebremariam, Yiyou Gu, Eman Youssef, Sondus Alkhazraji, Joshua Quran, Nathan P. Wiederhold, Ashraf S. Ibrahim
2024
86
n/a
-
v
Thomas Orasch (DE)
2024
85
n/a
-
v
Julien Alex, Katherine González, Gauri Gangapurwala, Antje Vollrath, Zoltán Cseresnyés, Christine Weber, Justyna A. Czaplewska, Stephanie Hoeppener, Carl-Magnus Svensson, Thomas Orasch, Thorsten Heinekamp, Carlos Guerrero-Sánchez, Marc Thilo Figge, Ulrich S. Schubert, Axel A. Brakhage
2024
84
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
83
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
82
n/a